Fakeeh Care (4017) fair value: what the stock is really worth
We calculate from audited financials what Fakeeh Care is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Fakeeh Care for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
27‑month range 28.70 SAR – 70.44 SAR · fair‑value band 16.09 SAR – 26.81 SAR · the 39.44 SAR price screens above the 21.45 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments.
Show more
Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. The company operates through Medical Services; Education; and Trading, Retail & Others segments. It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
Fakeeh Care (4017) currently trades at 39.44 SAR, while our model-based Fair Value estimate is 21.45 SAR, implying the stock looks roughly 83.9% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 26.56 SAR per share, and 1 of the 16 models we run sit above the 39.44 SAR price.
Bear case: the Dividend Discount group reads lowest at 4.54 SAR, and 15 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: 16.09 SAR (bear) to 26.81 SAR (bull), the price of 39.44 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Fakeeh Care reported revenue of 3.1B SAR in FY2025 versus 2.0B SAR in FY2021, a compound +12.0%/yr. Reported net income was 290M SAR in FY2025, compounding −3.5%/yr from FY2021.
Key figures
Market cap 9.1B SAR (≈ $2.4B) · P/E ratio 35.2 · P/S ratio 3.31 · EPS (TTM) 1.12 SAR · Dividend yield 0.8% · Net margin 9.4% · Return on equity 5.9% · Return on assets (EBIT) 7.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).
What moves the price
The share trades about 7% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −46%, 4017 screens richer than that median.
Fair Value models
Bear 16.09 SARFair Value 21.45 SARBull 26.81 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.5562 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.0%
Dividend (yield on the price)0.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 10%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 255 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−44% · Bottom 25%
Profitability
Return on equity (TTM)6% · Below median
Return on assets3% · Below median
Net margin (TTM)8% · Above median
Operating margin (TTM)6% · Below median
Growth and dividend
Revenue growth3% · Below median
Dividend yield (TTM)0.8% · Below median
Balance sheet
Debt / equity0.11× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)35.2× · Priciest 25%
P/B0.66× · Cheapest 25%
P/S (TTM)0.67× · Cheaper than median
EV/EBITDA5.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 29
FUTURE (revenue growth)17· sector 27
PAST (return on equity)24· sector 31
HEALTH (low debt)95· sector 90
DIVIDEND (yield)17· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fakeeh Care Fair Value". https://www.fairvalue-calculator.com/stock/4017
Frequently asked questions
Is Fakeeh Care (4017) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 21.45 SAR versus a price of 39.44 SAR, about −46% upside (overvalued).
What is the fair value of 4017?
Our model-based fair value for Fakeeh Care is 21.45 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 39.44 SAR.
What is the quality score of 4017?
Fakeeh Care has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fakeeh Care (4017)?
Our model-based price target is the fair value of 21.45 SAR (as of Sep 13, 2026) from 16 valuation models. Cautious scenario 16.09 SAR, optimistic scenario 26.81 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Fakeeh Care stock forecast for 2026?
Our models put fair value at 21.45 SAR, about −46% upside versus a price of 39.44 SAR (overvalued). Cautious scenario 16.09 SAR, optimistic scenario 26.81 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Fakeeh Care (4017)?
Fakeeh Care reported trailing-twelve-month revenue of about 3.1B SAR (latest available figure, as of Sep 13, 2026).
Does Fakeeh Care pay a dividend?
Fakeeh Care currently shows a dividend yield of about 0.84% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Fakeeh Care (4017)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fakeeh Care it is 21.45 SAR per share (as of Sep 13, 2026), against a price of 39.44 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Fakeeh Care stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 4017 trades above its calculated fair value: price 39.44 SAR, fair value 21.45 SAR, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4017?
No. The price is what the market pays today (39.44 SAR); the fair value is what the company's own numbers justify (21.45 SAR). For Fakeeh Care the two are 17.99 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Fakeeh Care worth?
The market values Fakeeh Care at about 9.1B SAR (market capitalisation, as of Sep 13, 2026). Per share that is 39.44 SAR; our models calculate a fair value of 21.45 SAR per share.
What do the bullish and bearish scenarios say about 4017?
Our models span a range for Fakeeh Care: cautious scenario 16.09 SAR, base 21.45 SAR, optimistic 26.81 SAR per share (as of Sep 13, 2026, price 39.44 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4017?
Fakeeh Care trades at a price-to-earnings ratio of 35.2 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.45 SAR is built from several models across several years. Other multiples: P/B 0.7, P/S 0.7, EV/EBITDA 5.0.
How solid is the balance sheet of Fakeeh Care (4017)?
Balance-sheet figures for Fakeeh Care (as of Sep 13, 2026): return on equity 5.9%, debt of 0.11 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 4017 from its 52-week high?
Fakeeh Care trades at 39.44 SAR, about 7% below its 52-week high of 42.46 SAR and 46% above the low of 26.96 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 21.45 SAR is for.
Which stocks are comparable to Fakeeh Care?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fakeeh Care stock attractive at the current price?
The data as of Sep 13, 2026: price 39.44 SAR, calculated fair value 21.45 SAR (−46%), Quality Score 37/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4017 calculated?
We run Fakeeh Care through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 21.45 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Fakeeh Care itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Fakeeh Care right now?
The price sits above even our optimistic bull case (26.81 SAR). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Fakeeh Care
How large is the market capitalisation of Fakeeh Care (4017)?
The market capitalisation of Fakeeh Care is 9.1B SAR (≈ $2.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fakeeh Care (4017)?
The price-to-sales ratio of Fakeeh Care is 3.31 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fakeeh Care (4017)?
Earnings per share at Fakeeh Care are 1.12 SAR (price ÷ EPS = P/E 35.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fakeeh Care (4017)?
The dividend yield of Fakeeh Care is 0.8% (payout 29.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fakeeh Care (4017)?
The net margin of Fakeeh Care is 9.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fakeeh Care (4017)?
The return on equity (ROE) of Fakeeh Care is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fakeeh Care (4017)?
On an EBIT basis the return on assets of Fakeeh Care is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fakeeh Care (4017)?
The operating margin of Fakeeh Care is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fakeeh Care (4017)?
Revenue at Fakeeh Care is growing +3.3% versus a year earlier (3y avg +15.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fakeeh Care (4017)?
Earnings per share at Fakeeh Care are growing −46.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fakeeh Care (4017) generate?
The free cash flow of Fakeeh Care is −48.5M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fakeeh Care (4017) carry?
The net debt of Fakeeh Care is 737M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Fakeeh Care in the live analysis
One click puts Fakeeh Care on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
